Selegiline Modulates Lipid Metabolism by Activating AMPK Pathways of Epididymal White Adipose Tissues in HFD-Fed Obese Mice.

Autor: Joung HY; Department of Physiology, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea., Oh JM; Department of Physiology, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea.; Research Institute for Endocrine Sciences, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea., Song MS; Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju 28644, Republic of Korea., Kwon YB; Department of Pharmacology, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea., Chun S; Department of Physiology, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea.; Research Institute for Endocrine Sciences, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea.
Jazyk: angličtina
Zdroj: Pharmaceutics [Pharmaceutics] 2023 Oct 27; Vol. 15 (11). Date of Electronic Publication: 2023 Oct 27.
DOI: 10.3390/pharmaceutics15112539
Abstrakt: Obesity, as a major cause of many chronic diseases such as diabetes, cardiovascular disease, and cancer, is among the most serious health problems. Increased monoamine oxidase (MAO) activity has been observed in the adipose tissue of obese humans and animals. Although previous studies have already demonstrated the potential of MAO-B inhibitors as a treatment for this condition, the mechanism of their effect has been insufficiently elucidated. In this study, we investigated the anti-obesity effect of selegiline, a selective MAO-B inhibitor, using in vivo animal models. The effect was evaluated through an assessment of body energy homeostasis, glucose tolerance tests, and biochemical analysis. Pharmacological inhibition of MAO-B by selegiline was observed to reduce body weight and fat accumulation, and improved glucose metabolism without a corresponding change in food intake, in HFD-fed obese mice. We also observed that both the expression of adipogenenic markers, including C/EBPα and FABP4, and lipogenic markers such as pACC were significantly reduced in epididymal white adipose tissues (eWATs). Conversely, increased expression of lipolytic markers such as ATGL and pHSL and AMPK phosphorylation were noted. Treating obese mice with selegiline significantly increased expression levels of UCP1 and promoted eWAT browning, indicating increased energy expenditure. These results suggest that selegiline, by inhibiting MAO-B activity, is a potential anti-obesity treatment.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje